News

Novartis secured the approval through a pharmacokinetic extrapolation strategy rather than a full pediatric RCT, leveraging adult HS trial data and existing pediatric PK modeling from other approved indications.

New case-control study data link tattoo exposure to a higher melanoma risk, prompting fresh scrutiny of ink chemicals and long-term skin safety.

On National Dermatologist Day, EltaMD unveils oil-balancing UV Clear SPF 50, clinically reducing the appearance of blemishes, shine, and pore size. Learn more in this Q&A with Seemal R. Desai, MD, FAAD, and Annie Woo, MD.

Mark Lebwohl, MD, reviews how the AdvanceAD-Tx 487-GEP test identifies which patients are likely to need a JAK inhibitor rather than a biologic.

Although the number of women leaders in Mohs surgery has increased, significant gender disparities remain in leadership roles, productivity metrics, and speaking opportunities.

On National Skin Barrier Day, dermatologists share barrier-saving tips for gentle cleansing, daily sunscreen, smarter product audits, and retinoid adherence.

Recent reviews highlight that melanoma risk associated with occupational UV exposure varies by tumor subtype, anatomical site, and individual susceptibility.

A split-face trial finds adding ivermectin to KTP laser modestly boosts rosacea redness reduction and cuts papules/pustules, without extra downtime.

Compared with topical regimens, Rossi notes PDT provides a shorter recovery window and fewer adherence challenges.

Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed clinical cases highlighting the distinct roles of topical ruxolitinib, tapinarof, and roflumilast in managing itch, inflammation, and long-term disease control in atopic dermatitis.

Mark Lebwohl, MD, discusses how the 487-GEP test may help clinicians identify the most appropriate systemic therapy for patients with AD earlier in the treatment journey.

A multicenter trial in China shows ALA-PDT clears Bowen’s disease in 97% with low recurrence, minimal scarring, and high patient satisfaction.

Researchers observed early reductions in acne lesions, with improvements beginning within 5 days of dermocosmetic treatment in patients with acne.

February highlights rare genetic skin diseases, shifting dermatology from supportive care to molecularly targeted therapies.

Results show that bimekizumab achieved significantly higher ACR50 response rates at week 16 than risankizumab in adults with active PsA.

FDA Fast Track boosts hopes for QRX003 lotion in Netherton Syndrome, with early trials showing rapid skin healing and itch relief.

This review of the latest dermatological studies includes insights on pediatric teledermatology rates pre- and post-COVID, a 10-peptide face serum for skin quality, AI-automated disease scoring, and more.

Needle-free botulinum toxin microjet TDA delivery cuts facial oil up to 40%, refines pores, and boosts confidence without bruising or downtime in acne patients.

A prospective study found that patch testing identified relevant allergens in 43% of patients with hand and foot eczema, with potassium dichromate being the most common sensitizer.

A new study reveals gaps in acne management for teens with PCOS; Hispanic patients are less likely to receive spironolactone, COCs, or isotretinoin treatment.

Red light–activated photodynamic therapy offers an effective field-based option for treating both visible and subclinical actinic keratoses.

Douglas DiRuggiero, DMSc, MHS, PA-C, emphasized that relying solely on body surface area underestimates psoriasis burden, particularly for patients with disease in high-impact or special areas.

Real-world data show IL-17 biologics rapidly improve special-site psoriasis and quality of life, as researchers identified predictors of PASI75/90 response.

Dylan Timmermann, PA-C, reflects on the experiences that shaped his career trajectory in dermatology and offers insights relevant to physician assistants and nurse practitioners entering the specialty.

A survey of dermatology residents found that interest in subspecialty fellowships often declines during training, with financial concerns particularly affecting pediatric dermatology.

NFBC1966 data from Finland show that hand eczema is associated with poorer self-rated work ability among middle-aged adults, particularly among those with certain risk factors.

Patients treated with deucravacitinib achieved higher ACR20 response rates at week 16 than those receiving placebo in the POETYK PsA studies.

A newly defined Nodularity Index, measuring tumor depth relative to width, independently predicted melanoma-specific survival.

A cover feature by Nicole A. Negbenebor, MD, FAAD, examines the growing leadership role of women in Mohs micrographic surgery for nonmelanoma skin cancer.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.